Z650 in Advanced Esophageal Squamous Cell Carcinoma With EGFR Over Expression or Gene Amplification
A Phase Ib, Multi-center, Open-label Study of Z650 in Advanced Esophageal Squamous Cell Carcinoma (ECSS) With Epidermal Growth Factor Receptor (EGFR) Over Expression or Gene Amplification
Sponsor: Sunshine Lake Pharma Co., Ltd.
Listed as NCT03888092, this PHASE1/PHASE2 trial focuses on Esophageal Squamous Cell Carcinoma and remains completed. Sponsored by Sunshine Lake Pharma Co., Ltd., it has been updated 9 times since 2017, reflecting limited change activity. This study contributes to the evolving evidence base for cancer treatment protocols.
Status Flow
Change History
9 versions recorded-
Sep 2024 — Present [monthly]
Completed PHASE1/PHASE2
-
Jul 2024 — Sep 2024 [monthly]
Completed PHASE1/PHASE2
Phase: PHASE1_PHASE2 → PHASE1/PHASE2
-
Apr 2023 — Jul 2024 [monthly]
Completed PHASE1_PHASE2
Status: Recruiting → Completed
-
Jun 2022 — Apr 2023 [monthly]
Recruiting PHASE1_PHASE2
Status: Active Not Recruiting → Recruiting
-
Apr 2021 — Jun 2022 [monthly]
Active Not Recruiting PHASE1_PHASE2
▶ Show 4 earlier versions
-
Jan 2021 — Apr 2021 [monthly]
Active Not Recruiting PHASE1_PHASE2
-
Nov 2020 — Jan 2021 [monthly]
Active Not Recruiting PHASE1_PHASE2
-
Apr 2020 — Nov 2020 [monthly]
Active Not Recruiting PHASE1_PHASE2
Status: Recruiting → Active Not Recruiting
-
Apr 2019 — Apr 2020 [monthly]
Recruiting PHASE1_PHASE2
First recorded
Aug 2017
Trial started
Per CT.gov start date — pre-dates our first snapshot
Eligibility Summary
No eligibility information available.
Contact Information
- Sunshine Lake Pharma Co., Ltd.
For direct contact, visit the study record on ClinicalTrials.gov .